Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emvododstat - PTC Therapeutics

Next Previous
X
Search
Drug Profile

Emvododstat - PTC Therapeutics

Alternative Names: DHODH 1; PTC-299

Latest Information Update: 16 Jan 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PTC Therapeutics
  • Class 3-ring heterocyclic compounds; Antineoplastics; Antivirals; Chlorinated hydrocarbons; Indoles; Phenyl ethers; Pyridines; Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III COVID 2019 infections
  • No development reported Acute myeloid leukaemia; Breast cancer; CNS cancer; Neurofibromatosis 2; Solid tumours
  • Discontinued Kaposi's sarcoma

Most Recent Events

  • 20 Jul 2022 PTC Therapeutics completes a phase-II/III clinical trials in COVID-2019 infections (Adjunctive treatment) in Greece, Australia, Brazil, Colombia, Italy, Mexico, Poland, Portugal, South Africa, Spain, USA (PO)
  • 20 Jul 2022 PTC Therapeutics completes a phase II/III trial in COVID-2019 in Belgium and France (EudraCT 2020-001872-13)
  • 28 Dec 2021 PTC Therapeutics terminates a phase-I clinical trial in Acute myeloid leukaemia (Second-line therapy or greater) in USA (PO) (NCT03761069)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top